INTRODUCTION
Hypoxia is a common feature of solid tumors in animals and in human patients, and has been documented in thousands of papers and in reviews by our group and many others (see refs. 1-7). Tumors develop regions of severe hypoxia, with oxygen tensions as low as 1 Torr or less, very early in their development; primary and metastatic tumors with diameters of less than 1 mm have already developed areas of severe hypoxia (1-3, 5-7). As solid tumors grow, they concomitantly elicit the development of vascular beds that support the malignant cells through processes of angiogenesis, neovascularization, and co-option of vessels from normal tissues (5, 7) . However, the tumor vascular bed that develops during this process lacks the organization and regulation found in the vasculature that supports healthy normal tissues. The vessels are tortuous and irregular; blind ends, shunting and other defects are common. The vessels also lack the musculature needed to precisely regulate blood flow and frequently have microscopic leaks or even macroscopic holes that permit plasma or blood to escape into the surrounding tissue (5, 7) . In addition, the growing tumor may invade or compress blood and lymphatic vessels, which further compromises their functionality. As a result, perfusion within solid tumors is abnormal and inadequate, and tumors contain regions where temporary interruptions in blood flow through individual vessels or persistent deficiencies in perfusion lead to transient and chronic hypoxia (1) (2) (3) (4) (5) (6) (7) . Because molecular oxygen is a potent radiosensitizer, the hypoxic cells in these regions are resistant to radiation (1) (2) (3) (4) . These radioresistant cells can survive radiation regimens that would eradicate fully aerobic cell populations and can cause tumors to recur after radiation therapy (1) (2) (3) (4) . Intensive efforts have therefore been devoted to improving the outcome of radiation therapy by combining radiation with drugs that improve tumor oxygenation, selectively sensitize hypoxic cells to radiation, or preferentially kill hypoxic cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Interest in these approaches has re-intensified recently due to the increased use of stereotactic radiosurgery, high-dose-rate brachytherapy, and hypofractionated IMRT regimens that deliver radiotherapy as a few high dose fractions, rather than as highly fractionated radiotherapy with many smaller fractions (15, (17) (18) (19) . Radiobiology studies (2, 16) , clinical findings (15) and mathematical models (17) (18) (19) have shown that the radioprotective effects of hypoxia become increasingly important with radiotherapy regimens that use very large single doses or a few large fractions. The effectiveness of oxygen modulation, radiosensitizers, or hypoxic cell cytotoxins as adjuvants to radiotherapy therefore would be increased when they are used with hypofractionated and single-dose regimens.
Several classes of agents with preferential cytotoxicity to hypoxic cells have been identified, including quinones, nitroimidazoles, benzotriazoles and several other classes of bioreductive alkylating agents and metabolic inhibitors (8) (9) (10) (11) (12) (13) (14) (15) . Many have shown good differential toxicities in cell culture studies, and some have shown promising effects in animal model systems (3, 13) . Some have been tested in clinical trials as adjuncts to potentially curative radiation therapy regimens or as additions to radiation/drug regimens. The results of these clinical trials have been mixed: some have shown improvements in local control and disease free survival that support the merit of the approach, while others have shown no improvement in tumor response or have shown increased toxicities from the combined modality regimen that resulted in a lack of therapeutic gain from the combination (12) (13) (14) (15) . There is a need for better hypoxiaselective cytotoxic agents that produce better therapeutic outcomes.
The bioreductive alkylating agent KS119, 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]-carbonyl]hydrazine), developed in the Sartorelli laboratory at Yale, had an extremely large differential in its toxicity to severely hypoxic and aerobic cells in cell culture, and was effective in killing hypoxic cells of EMT6 mouse mammary tumors in vivo, as measured using a clonogenic assay (11, (20) (21) (22) (23) (24) . However, the limited solubility of this compound precluded development as a potential anticancer drug. Further studies in the Sartorelli laboratory and at Vion Pharmaceuticals resulted in the development of an analog, KS119W, that has increased aqueous solubility due to the addition of a phosphate group. The octanol:water partition coefficients were 151 for KS119 and 22.5 for KS119W (24) . Both KS119 and KS119W are prodrugs that require enzymatic nitroreductive activation, which occurs preferentially in hypoxic cells, to generate 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine (90CE), which in turn, generates the alkylating species that produces DNA crosslinks (11, (20) (21) (22) (23) (24) . The molecules consist of three domains (25) , a ''trigger region'' consisting of a nitro group, a benzyloxycarbonyl ''linker'' region, and a ''therapeutic warhead'' or ''effector'' region that consists of the cytotoxic crosslinking moiety 90CE (Fig. 1) . The synthesis, chemistry, and biochemistry of KS119, KS119W, 90CE and some related compounds are described in publications from the Sartorelli laboratory (11, (20) (21) (22) (23) (24) . The studies reported here compare the cytotoxicities of KS119 and KS119W to aerobic and hypoxic EMT6 cells in cell culture, and examine some environmental and cellular factors that influence the cytotoxicity of the newer analog, KS119W, to cells in vitro. We also present studies that examine the antineoplastic effects of KS119W alone and in combination with radiation using EMT6 tumors in BALB/c mice, and compare these effects with those seen for KS119.
MATERIALS AND METHODS

Cell Lines and Cell Culture Techniques
The cell culture experiments described here used EMT6 mouse mammary tumor cells maintained as monolayer cultures at 378C in an atmosphere of 95% air/5% CO 2 . EMT6 cells have been used extensively in the authors' laboratories and their characteristics are well defined (1-4, 8-10, 16, 21-24, 26-40) . Two features of EMT6 cells are important in these studies. First, they lack detectable O 6 -alkylguanine-DNA alkyltransferase (AGT), which is also known as O 6 -methylguanine DNA-methyltransferase (MGMT) (23, 26, 30) . Second, they can be grown as solid tumors in mice, as well as in cell culture (27, 28, (31) (32) . EMT6 cells were maintained in Waymouth's Medium with 15% fetal bovine serum and antibiotics. EMT6 cells transfected with murine and human AGT cDNAs were developed and characterized by Ishiguro (30) and Baumann (23) , respectively, and were cultured in McCoy's 5A medium with 10% fetal calf serum and antibiotics. When being compared with these transfected cells, parental EMT6 cells were also grown in McCoy's 5A medium. All cell culture media, trypsin, and antibiotics were obtained from GIBCO (Invitrogen, Carlsbad, CA), and all sera were obtained from Gemini Bioproducts, West Sacramento, CA.
Unless otherwise noted, cell cultures were plated in standard 60 mm cell culture dishes using the media described above, and were treated in mid exponential growth under aerobic conditions (95% air/5% CO 2 ) in a standard cell culture incubator. Cultures were treated with drug and/or radiation as described below and the cell monolayers were then washed, trypsinized, and suspended to form single cell suspensions. The suspended cells were assayed for survival using colony formation assays as described previously (27, 28, 33) . Surviving fractions were calculated relative to the plating efficiencies of untreated control cultures plated in the same experiments (33) . Cell numbers in treated KS119W: A HIGHLY SELECTIVE HYPOXIC CELL CYTOTOXIN and control cultures were compared to detect any rapid cell death occurring during treatment, which could compromise the clonogenic assays. Cell numbers in cultures treated with high concentrations of KS119W (!25 lM) in hypoxia were lower than those in control cultures at the end of the 2 h treatment. Because of this, the doseresponse curves shown in Fig. 2 are shown as yield-corrected surviving fractions, which consider the decrease in the numbers of cells in the treated cultures as well as the decrease in the plating efficiencies of the suspended cells (28, 31, 33) . In all other experiments, which used shorter incubation times, aerobic incubations, and/or lower concentrations, no changes in the number of cells in treated cultures were observed, and data are therefore shown as surviving fractions.
In experiments examining the cytotoxicity of drugs to hypoxic cells in culture, cells were plated in glass milk dilution bottles and used in mid exponential growth. Cultures were made severely hypoxic by sealing the bottles with rubber gaskets, inserting needles for the influx and efflux of gases, and gassing for 1 h with a humidified mixture of 95% nitrogen/5% CO 2 certified by the vendor (TechAir, New Haven, CT) to contain ,1 ppm O 2 (0.00001% O 2 ). KS119, KS119W or vehicle was injected through the septum of the gasket, without breaking the hypoxia, and cultures were incubated with this agent under continued hypoxia for 2 h as described previously (8, 29, 31, 34) . Controls exposed to hypoxia plus vehicle were included in all experiments. When comparing the cytotoxicities of KS119 and KS119W under air and hypoxia, aerobic and hypoxic cultures were studied in the same experiments.
In experiments examining the effects of pH on the cytotoxicity of KS119W, 25 mM HEPES [4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid] was added to the culture medium to be used for cells incubated at pH 7.2, the medium was equilibrated at 378C in a standard cell culture incubator, and the pH was carefully adjusted to 7.2 just before treatment using sterile 1 M HCl or NaOH solutions. For cultures to be treated at pH 6.0, 25 mM MES [2-(N-morpholino) ethanesulfonic acid] was added to the culture medium, the medium was equilibrated at 378C in a standard cell culture incubator, and the pH was adjusted to 6.0 just before use. The medium overlying the cultures was removed and the cells were washed twice with 378C medium adjusted to a pH of either 7.2 or 6.0, then re-covered with that same medium. Ten minutes later, KS119W was added to the medium and cells were incubated with the agent for 30 min, then washed, trypsinized, suspended and plated for the measurement of colony formation. For treatment under hypoxia, cultures in glass bottles were prepared and treated as described above, except that the medium was changed to medium adjusted to the appropriate pH (7.2 or 6.0) just before gassing, and the cultures were then gassed with nitrogen, as described above, for 1 h before treatment with KS119W. Short incubations (30 min) with KS119W were used in all these experiments to ensure that the pH of the medium remained relatively constant throughout the drug treatments, as our past studies showed that the pH of the culture medium tends to normalize with time, even in heavily buffered cultures (34) .
Tumor Studies
All experiments with tumors in vivo were performed using BALB/c Rw mice 2.5-3.5 months of age that had been bred and raised in our specific pathogen free production colony. All protocols used with experimental animals were reviewed and approved by the Yale Institutional Animal Care and Use Committee, and all experiments were performed in full compliance with the regulations and policies of the government, Yale University, and the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) and with the principles outlined in the Guide for the Care and Use of Laboratory Animals. Tumors were produced by inoculating 2 3 10 5 EMT6 cells, harvested from exponentially-growing cell cultures, intradermally into the flank, and were treated with KS119, KS119W or radiation approximately 2 weeks later, when the tumor volumes averaged 100 mm 3 (27, 31, 32) . Past studies in our laboratory have shown that in EMT6 tumors of this volume the hypoxic fraction (i.e., the proportion of the viable clonogenic tumor cells that are radiobiologically hypoxic as shown by rigorous analyses of paired tumor cell survival curves or tumor growth delay curves) is approximately 30% (1, 2). In addition, studies with oxygen microelectrodes have examined regional variations in pO 2 within these tumors and have shown the expected distribution of oxygen tensions, with many areas having severe hypoxia, with pO 2 levels of ;1 Torr (36, 37). Measurements of extracellular pH using microelectrodes have shown regional variations in pH, with pH varying from 7.2 to 5.9 within the tumors (35) . Other studies have shown that the oxygenation of the tumors can be improved by appropriate concomitant treatments with hyperbaric oxygen, carbogen, perflourochemical emulsions, allosteric effectors of hemoglobin, texaphyrins, or pentoxyfiline, and that these treatments provide the anticipated improvements in the response of the tumors to irradiation (2-4, 37-39). Past studies have also shown that hypoxic cell radiosensitizers such as misonidazole increase the radiosensitivity of the hypoxic tumor cells (3, 10, 27) , and that drugs preferentially toxic to hypoxic cells, including mitomycin C, porfiromycin and KS119, as well as misonidazole, kill cells in the tumor cell populations that demonstrate hypoxic radioresistance (3, 9, 10, 21, 35, 40) . These past studies therefore indicate that EMT6 tumors of the size examined here contain large numbers of radiobiologically hypoxic cells that are critical in determining the response of the tumors to large doses of radiation and to many combined modality regimens.
Tumor cell survival was measured using a colony formation assay. Mice were randomized into treatment groups and exposed to KS119W, radiation, or a combination of the two agents as described below. At the time of assay, the mice were euthanized, tumors were explanted sterilely and a single cell suspension was created by mincing and trypsinization as previously described in detail (27, 31, 33) . Cells were collected by centrifugation, resuspended in Waymouth's medium, counted under a phase contrast microscope using trypan blue to determine the number of cells damaged during the suspension process, and plated for colony formation as described above briefly for cells from culture and detailed elsewhere (27, 31, 33) . The numbers of cells suspended from untreated and treated tumors were examined and compared to detect any rapid cell loss during treatment; cell loss was not observed in these studies. Surviving fractions were calculated using the plating efficiencies of cells from untreated control tumors plated on the same day, which averaged 27 6 2% in the experiments reported here.
In tumor growth delay studies, three diameters of each tumor were measured three times per week with vernier calipers and tumor volumes were calculated using the formula for the volume of a hemiellipsoid (27, 31, 32) . When the tumors reached an average volume of 100 mm 3 , they were stratified by volume into control and treatment groups, which were treated with radiation, KS119, KS119W, radiation plus KS119, or radiation plus KS119W as described below. Mice were then monitored and tumor volumes were measured three times per week until each tumor reached a volume of 1,000 mm 3 . The effects of treatment on tumor growth were assayed by determining the times for treated and control tumors to grow from the treatment volume to 4 times that volume and calculating the growth delays as described previously (27, 31, 32) . At the start of the experiment and each time the tumors were measured, mice were also weighed and examined to monitor their health status as assessed by their behavior (activity level, response to handling, gait, ease of motion, grooming behavior, fecal output and appearance) and their appearance (fur condition, eyes, skin color).
KIM ET AL.
Treatments KS119 and KS119W were provided without cost by Vion Pharmaceuticals. For cell culture studies, KS119 was dissolved in dimethyl sulfoxide (DMSO; JT Baker, Phillipsburg, NJ). KS119W was dephosphorylated by dissolving the stock powder in 50 mM Tris-HCL, 0.1 mM EDTA, pH 8.5, addition of 2 ll of AP enzyme (40 units; Roche) and incubation for 30 min at 378C. The KS119W-OH precipitated and was redissolved by the slow addition of an equal volume of DMSO. For studies in mice, KS119 was dissolved in 1:2 DMSO:Cremophor EL (Sigma), and was diluted with sterile pyrogenfree distilled water just before intraperitoneal injection. KS119W was dissolved in sterile pyrogen-free Tris 0.3 M buffer, which was then diluted 1:1 with distilled water immediately before intraperitoneal injection. Groups treated with the vehicles at the highest doses used were included in the experiments to detect any effects of the vehicles; none were observed.
Cell cultures were irradiated with 320 kV X rays produced by an XRAD (Precision X-ray, Branford, CT) at 12.5 mA, 2 mm Al filtration and a dose-rate of 2.6 Gy/min. In tumor growth studies, mice were anesthetized with ketamine/xylazine and were positioned with the body shielded. The tumors were then irradiated locally with 250 kV X rays produced by a Siemens Stabilipan (Malvern, PA) at 15 mA, 2 mm Al filtration and a dose rate of 6.4 Gy/min. Because the X ray doses received by the intestines, bone marrow and other critical normal tissues were less than 5% of the tumor dose, these mice had no significant systemic injuries from the radiation. Because the radiation times were short, and a relatively light, short acting anesthetic dose was used, the temperature of the mice remained near normal. In the tumor cell survival studies, mice were loosely confined in individual chambers of a well ventilated Lucite irradiation box that gently restrained the mice in an upright and constant position so that the tumor position was consistent and the dose to the tumors was uniform. the mice were whole-body irradiated with 250 kV X rays produced by a Siemens Stabilipan at 15 mA, 2 mm Al filtration and a dose-rate of 1.1 Gy/min.
For regimens combining radiation and KS119 or KS119W in vivo, radiation was always given 2 h after injection. When the cell survival assay was used, tumors were always removed for assay 6 h after injection of KS119W or 4 h after irradiation. The time between tumor irradiation and assay for cell survival was held constant throughout the experiments reported here, because quiescent EMT6 cells in culture and in solid tumors have been shown to be proficient in the repair of potentially lethal damage (29) . The delay of 4 h before plating and assaying for cell survival allowed repair of potentially lethal damage to occur and avoids the potential artifacts that would result if cell survival were to be assayed at different times after irradiation in different groups.
For regimens combining KS119W and radiation in aerobic cell cultures, KS119W was added to the culture medium 2 h before suspension of cells to assay cell survival. Cultures were irradiated during the last few minutes of the KS119W exposure and cell survival was assayed immediately after irradiation. Experiments examining the effects of KS119W on the radiation response of hypoxic cells required use of a different procedure, so that cells could be transported to the irradiator and irradiated under hypoxia (28, 40) . In these experiments, monolayers were plated as described above but were planted into Permanoxe Petri dishes (MP Biomedicals, Solon, OH), which are specially designed to allow the induction of rapid hypoxia. Cultures were allowed to grow to mid-exponential growth. The medium on the cultures was removed and replaced with 2 ml of medium containing KS119W, and the cultures were then placed in a stainless steel pressure vessel and gassed with the humidified mixture of 95% nitrogen/5% CO 2 , as described above, for ;1 h. The vessels were then sealed to preserve the hypoxic atmosphere, carried to the irradiation room and irradiated as described above. Cultures were maintained in hypoxia for a total of 75 min, with graded doses of radiation given during the last few minutes of the hypoxic incubation.
The effects of regimens combining the two agents were analyzed by considering the dose-response curves for each agent individually, as well as the data for the combined treatments following the principles described by Steel (41) .
RESULTS
Cell Culture Studies
Effects of hypoxia. The experiments shown in Fig. 2 compare the cytotoxicity of KS119 and KS119W to EMT6 cells in exponential growth in cell culture. The cytotoxicities of the two compounds to cells that were severely hypoxic at the time of drug treatment were similar. KS119W had slightly greater toxicity to aerobic cells than did KS119 at concentrations approaching the limit of solubility of KS119. The studies shown in Fig. 2 could be extended to higher concentrations with KS119W because of the greater solubility of this compound. KS119 and KS119W had similar cytotoxicities to hypoxic cells throughout the range of the measured cell survival curves. The differential in the cytotoxicities of both compounds in air and hypoxia is notable. At the highest dose of KS119W that could be tested, the yield corrected surviving fraction for aerobic cells is approximately a million times higher than that for severely hypoxic cells.
Effects of pH. The reductive activation of some bioreductive alkylating agents to cytotoxic species is dramatically increased at low pH as well as in hypoxia (34, 42, 43) , with low pH producing an increase in toxicity similar to that produced by hypoxia. To assess whether pH affected the cytotoxicity of KS119W under aerobic conditions, the medium on exponentially growing cultures was removed and the cells were washed with 378C medium that had been adjusted to a pH of either 7.2 or 6.0 as described in the Methods and Methods, then re-covered with medium at that same pH. Ten minutes later, KS119W was added to the medium and cells were incubated (Fig.  3 ). The KS119W treatments tested showed only insignificant toxicities at physiologic pH. The surviving fractions at the extremely acidic pH were significantly lower only at the highest concentration tested, 50 lM, which produced a surviving fraction of 0.61 6 0.08 at pH 6.0 compared with the surviving fraction of 0.96 6 0.05 for cells at pH 7.2. Extracellular pH had only minimal effects on the cytotoxicity of KS119W in hypoxia over the range of survivals studied (Fig. 3) . The minimal effects of pH on the cytotoxicity of KS119W under both aerobic and hypoxic conditions were in marked contrast to the very large effects of hypoxia on the cytotoxicity of this compound at either low or physiologic pH. In these experiments, incubation of cells with KS119W in severe hypoxia for 30 min produced a dramatic increase in the cytotoxicity of the drug (Fig. 3) , as was expected from the more extensive data shown in Fig. 2 .
Effects of AGT. KS119W is thought to produce its cytotoxicity through enzyme-catalyzed reductive fragmentation of the molecule to an alkylating intermediate, 90CE, which produces DNA crosslinks. To test the importance of DNA alkylation in the cytotoxicity of KS119W, we examined the effects of the repair protein O 6 -alkylguanine-DNA alkyltransferase, which is also known as O 6 -methylguanine DNA-methyltransferase, on the toxicity of Notes. Five mice per group were used in experiment 1; 8 mice per group were used in experiments 2 and 3. The ''growth delay'', the excess time needed for the each tumor to grow from the volume at the time of treatment to 4 times the treatment volume, was calculated as described previously (31, 32) and are shown as means 6 SD. *Significantly different from control (paired t test, P , 0.05).
þ Significantly different from radiation only (paired t test, P , 0.05). ND ¼ Not determined.
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KS119W to hypoxic EMT6 cells (Fig. 4) . AGT transfers guanine O 6 -alkyl groups to the cysteine in the active site of AGT and thereby restores the O-6 position of the guanine to its native state, preventing the formation of crosslinks (11, 29-24, 26, 30) . EMT6 cells transfected with the gene for either human or mouse AGT, and expressing either 10,000 molecules/cell of mouse AGT or 18,000 molecules/cell of human AGT, respectively, showed markedly increased resistance to the cytotoxic effects of KS119W in hypoxia (Fig. 4) . In contrast, the sensitivity of cells transfected with the empty vector was similar to that of the parental EMT6 cells, which lack detectable AGT. KS119W plus radiation in vitro. If KS119W is used clinically as a hypoxic cell cytotoxin, it will likely be given in combination with radiation therapy because radiation is preferentially toxic to aerobic cells. It also would likely be given shortly before radiation to maximize the therapeutic gain derived from the differential toxicities of the agents to cells in the aerobic and hypoxic environments. This would result in significant tissue levels of KS119W at the time of irradiation. Therefore, we examined the effects of treatment with high concentrations of KS119W before and during irradiation on the radiation-dose response curve for aerobic cells. At the high concentration used in these experiments (150 lM), KS119W alone had some cytotoxicity to the aerobic cultures, reducing the survival of the cells to 0.39 6 0.14. When the survival curve for the two agents combined was corrected for the toxicity of the KS119W, the 2 radiation-dose response curves were indistinguishable (Fig.  5) . KS119W did not alter the radiation response of aerobic EMT6 cells when given in a concentration close to its limit of solubility and well above concentrations that would be achievable in vivo.
The effect of KS119W on the radiosensitivity of hypoxic cells was also examined. Because of the greater cytotoxicity of KS119W in hypoxia (Fig. 2) , a lower dose of KS119W (2 lM) and a shorter incubation time than those used with aerobic cells were used. Concomitant treatment with this dose of KS119W did not alter the radiation response of hypoxic EMT6 cells significantly (Fig. 5) .
Studies with Solid Tumors in Mice
The cytotoxicity of KS119W to the cells in solid EMT6 tumors was examined using a clonogenic assay to measure the viability of cells suspended from the tumors. As the pharmacokinetics and distribution into tumors of KS119W had not yet been studied, we did not know the duration of exposure of the tumor cells in vivo to effective concentrations of KS119W. We therefore began by measuring the surviving fraction of the tumor cells as a function of time after injection of KS119W (Fig. 6 ). Studies at a dose of 180 mg/kg, the highest dose that could be given in a single injection, showed that the survival of the tumor cells fell as the time after injection increased from 0 to 4 h, then plateaued as the time increased from 4 to 8 h. Limited studies with a dose of 60 mg/kg were compatible with these data, showing a decrease in the survival of the cells between 2 and 6 h. No change in the number of cells suspended from the treated tumors relative to the control tumors was observed for either dose at the times of these assays, showing that there was no rapid loss of cells killed by KS119W. In subsequent experiments shown below, the survival of the tumor cells was always measured 6 h after injection of KS119W to ensure full cytotoxicity. Figure 7 shows the survival curves for cells from EMT6 tumors treated with radiation, KS119W, or combinations of the two agents. The left panel of Fig. 7 shows the dose response curves for cells in tumors treated with graded doses of KS119W alone and in combination with 15 Gy of radiation. KS119W was injected 2 h before irradiation and cell survival was always measured 6 h after administration of KS119W (i.e., 4 h after irradiation). The time of 2 h between injection of KS119W and irradiation was selected on the basis of the data shown in Fig. 6 to ensure that irradiation was delivered at the time when KS119W was present in the tumors and actively killing tumor cells. The time between irradiation and assay of cell survival was held KS119W: A HIGHLY SELECTIVE HYPOXIC CELL CYTOTOXIN constant at 4 h throughout these experiments to ensure that the repair of potentially lethal radiation damage (29) was the same in all groups, KS119W alone reduced the survival of cells in unirradiated tumors in a dose-dependent manner, killing about 90% of the tumor cells at the highest dose tested (Fig. 7) . The dotted line re-plots the dose response curve for tumors receiving KS119W plus 15 Gy of X rays after normalization to the surviving fraction for radiation alone, to facilitate a visual comparison of the dose response curves for KS119W with and without concomitant irradiation. At doses of 100 and 180 mg/kg, the effects of KS119W were greater in irradiated tumors than in unirradiated tumors, suggesting that the drug was slightly more effective against the tumor cell population that survived concomitant high-dose irradiation. These data are statistically compatible with either additive or slightly supra-additive cytotoxicities.
The right panel of Fig. 7 shows survival curves for cells from tumors treated with graded doses of radiation alone and in combination with 180 mg/kg KS119W. In these experiments, KS119W was again injected 2 h before irradiation and cell survival was measured 6 h after administration of KS119W (i.e., 4 h after irradiation). The dotted line re-plots the survival curve for tumors treated with KS119W plus radiation normalized to the survival of cells in tumors treated with KS119W alone, to facilitate visual comparison of the dose-response curves for KS119W with and without concomitant irradiation. This dotted curve lies slightly below the curve for radiation alone, indicating that KS119W killed slightly more cells in the population that survived concomitant irradiation than it killed in the overall tumor cell population. These data are statistically compatible with either additive or slightly supra-additive cytotoxicities.
The tumor growth delays determined in 3 studies using a tumor growth assay to compare the effects of KS119 and KS119W on the growth of EMT6 tumors are summarized in Table 1 . The full tumor growth curves showing tumor volumes as a function of time for one representative experiment are shown in Fig. 8 . In these experiments, KS119 alone at a dose of 110 mg/kg did not produce a statistically significant change in the growth of the tumors in either experiment in which it was tested or when the pooled data were tested. The growth of tumors treated with KS119W at the same dose (110 mg/kg) was significantly slower than that of the control tumors in 1 of the 3 experiments, and the increase in delay was not statistically significant in the other two experiments. However, the difference between the growth of KS119W-treated and control tumors was statistically significant when data from the 3 experiments were pooled.
As expected, 10 Gy of localized irradiation produced an increase in the time needed for the tumors to reach 4 times the treatment volume. Although the time needed to reach 4 times the treatment volume was numerically greater when mice received KS119 as well as irradiation, the growth delays were not significantly different from those obtained with radiation alone in either individual experiment. There was a significant difference when the pooled data were tested. The growth delays in mice treated with KS119W plus radiation were significantly different from those in mice treated only with radiation in all 3 individual experiments, as well as for the pooled data (Table 1) .
Additional groups that were included in the third experiment in Table 1 , but were not shown in that table, also examined the effect of a higher dose of KS119W (180 mg/kg) alone and in combination with 10 Gy. In this experiment, 180 mg/kg KS119W alone produced a growth delay of 1.7 6 1.2 (mean 6 SD) days, which was not significantly different from the control. The combination of 180 mg/kg KS119W and 10 Gy produced a delay of 9.3 6 1.0 days, which was significantly greater than the delay produced by radiation alone in the same experiment (1.7 6 1.9, Table 1 ).
At the doses used in the experiments shown in Table 1 , neither KS119 nor KS119W produced discernable toxicities in the host mice as assessed using a scale that considers both behavior (activity level, response to handling, gait, ease of 132 motion, grooming behavior, fecal output and appearance) and appearance (fur condition, eyes, skin color). In addition, the weights of the mice were measured at each tumor measurement and the weights in the different treatment groups were similar throughout the duration of the tumor growth studies. The use of KS119W as an adjunct to radiation in these experiments therefore not only produced a significant increase in the tumor growth delay, providing a significant increase in the efficacy of the treatment regimen, but also increased the therapeutic ratio, because this therapeutic benefit was obtained without an increase in toxicity to the host mice.
DISCUSSION
The experiments described here examined the effects of a new hypoxic-cell cytotoxin, KS119W, on EMT6 cells in vitro and on EMT6 tumors in vivo. KS119W is a novel compound. Like the lead compounds in this series, it is a prodrug that requires enzyme-mediated nitroreductive activation, which occurs preferentially in hypoxic cells, to generate 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine (90CE), the alkylating species that produces DNA crosslinks (11, (20) (21) (22) (23) (24) . KS119W had a strong preferential cytotoxicity to EMT6 cells that were severely hypoxic during treatment with the compound (Fig. 2) . At the highest concentration tested, which approached the limit imposed by the solubility of the agent, the yield corrected surviving fractions of the aerobic and hypoxic cells differed by a factor of 1 million. The concentrations needed to produce similar cytotoxic effects in air and hypoxia also differed markedly. A 2 h treatment in air with 150 lM KS119W (the highest concentration that could be tested) reduced the surviving fraction of EMT6 cells to ;10%, while only 2 lM KS119W was required to produce a similar cytotoxic effect under hypoxic conditions. This 75-fold difference in the isoeffect concentration is similar to that reported for tirapazamine (12, 14) , and much greater than those seen with mitomycin C (twofold) (8, 34) , porfiromycin (fivefold) (40) , and many other bioreductive alkylating agents (12) (13) (14) . Equal doses of KS119 and KS119W had similar cytotoxicities. The greater aqueous solubility of KS119W allowed the use of higher concentrations of that compound, which produced greater cytotoxicities.
The cytotoxicity of KS119W differs from that of mitomycin C, porfiromycin and tirapazamine in an important regard: decreasing the extracellular pH from physiologic range to 6.0 had only minimal effects on the cytotoxicity of KS119W. Our previous studies (34) showed that the cytotoxicity of a 30 min treatment of EMT6 cells with 2 lM mitomycin C under aerobic conditions increased by 50-fold as the extracellular pH decreased from the physiologic range (7.2-7.4) to 6.0. We hypothesized previously (34, 42) that the increased effects of mitomycin C at low pH under aerobic conditions could be responsible for certain uncommon but potentially life-threatening toxicities seen with mitomycin C in the clinic, which have severely limited the clinical use of that drug. Subsequent studies in our laboratory 3 showed a similar increase in the cytotoxicity of porfiromycin at low pH in air, and also showed that the cytotoxicities of mitomycin C and porfiromycin in severe hypoxia were not altered significantly when the extracellular pH was reduced to ;6.0. Measurements of the pH within EMT6 tumors using microelectrodes have shown that the pH within these tumors is generally much lower than that in normal tissues. The median pH in EMT6 tumors was 6.5 and ;10% of the measured pH values were in the range of 5.9-6.1 (35) . We hypothesized previously that the increased cytotoxicity of mitomycin C and porfiromycin at low pH in air contributed We also hypothesized that the greater toxicities of those drugs to aerobic cells at low pH diminished the preferential toxicity of these drugs to hypoxic tumor cells in vivo from that seen in cell culture studies, because some aerobic tumor cells would be expected to be in low pH environments, while during the cell culture studies the pH of both aerobic and hypoxic cells was always maintained in the physiologic range.
Skarsgard and his collaborators (43) showed a large effect of pH on the aerobic cytotoxicity of tirapazamine in HT-29 cells. In aerobic cells, the survival of cells treated with 1,000 lM tirapazamine in air fell continually as the extracellular pH decreased from ;7.4 to 6.0, from a survival of approximately 10% at physiologic pH to a value of about 0.1% at pH 6.0. In contrast, the survival of HT-29 cells treated with 40 lM tirapazamine in hypoxia remained constant at about 5% over the same range of extracellular pH. Skarsgard et al. (43) also reported a similar effect of pH on the cytotoxic effects of tirapazamine in SiHa cells. They suggested that the increased effects of tirapazamine at low extracellular pH could play a role in both the antineoplastic effects and the host toxicities of tirapazamine, which in combined modality regimens have included ototoxicity, muscle cramping, peripheral neuropathy, and GI symptoms (12) . Effects of extracellular pH on efficacy that reflect differences in uptake, metabolism, or lesion production have also been reported for other alkylating agents, hypoxia selective cytotoxins, and chemotherapeutic drugs (44) (45) (46) (47) (48) (49) , sometimes increasing and other times decreasing the efficacy of the drugs in vitro and/or in vivo. The minimal effect of extracellular pH on the cytotoxicity of KS119W under either aerobic or hypoxic conditions could therefore be important to the antineoplastic effects and toxicities of this agent, and suggests that the toxic effects of KS119W in vivo could be different from those observed for the hypoxiaselective cytotoxins that are activated to cytotoxic intermediates under aerobic conditions at low pH as well as in hypoxia.
The decreased cytotoxicity observed with KS119W in EMT6 cells transfected to express the DNA repair protein AGT further confirms the proposed mechanism of action of this agent as being alkylation of guanine O-6 in DNA and the subsequent production of cytotoxic crosslinks (11, (20) (21) (22) (23) (24) . Cell culture studies combining high concentrations of KS119W with radiation under aerobic conditions showed only additive toxicities of the two agents and provided no evidence to suggest that this agent should sensitize normal tissues in vivo, which are generally relatively well aerated, to irradiation. Studies combining KS119W with radiation under hypoxic conditions in vitro likewise showed only additive cytotoxicities for the two agents. Overall, these data show that KS119W does not act as a radiosensitizer, and suggest that the effects of regimens combining KS119W and radiation in vivo should reflect the combined cytotoxicities of the two agents, Data for tumors treated with KS119W and radiation in vivo are in agreement with this conclusion from our cell culture studies. These tumor response data showed that the effects of the regimens combining the two agents reflected the cytotoxicities of the two agents, and provided no evidence for radiosensitization of solid tumors by KS119W (which would have been evidenced by an increase in the terminal slope of the radiation dose-response curve). The lack of radiosensitizing effects was as expected from the structure of KS119W and the biochemical data on the compound.
Tumor cell survival studies and tumor growth studies both showed significant effects of KS119W on EMT6 tumors in vivo. Although the cytotoxicities and growth delays seen in our studies with KS119W alone are relatively modest, it should be noted that the EMT6 tumor cell line is quite resistant to radiation and very resistant to many anticancer drugs (27, (50) (51) (52) . The growth delays and in vivo cytotoxicities seen with KS119W in these studies were often similar to those observed in the same experiments with 10 Gy of radiation. The effects of KS119W were also greater than those seen in our past studies with maximally tolerated single doses or maximally attainable concentrations of many widely used anticancer drugs, including 5-fluorouracil, doxorubicin, paclitaxel and carboplatin (50) (51) (52) . Moreover, the maximal doses of KS119W that could be administered in the studies reported here were limited by the solubility of the compound, and not by host toxicities. KS119W produced no discernable toxicities to the animals in these studies. In sharp contrast, the standard chemotherapeutic drugs described above were tested in vivo at doses that produced significant toxicities to the host mice. The significant antineoplastic activity of KS119W alone, in the absence of discernible host toxicity, is therefore notable.
The addition of KS119W to radiation increased the antineoplastic effects over those observed with radiation alone without producing discernibly greater host toxicities. These combinations therefore increased the therapeutic ratio and produced therapeutic gain when compared with radiation alone. Also, these studies suggest that further experiments examining fractionated regimens combining radiation and KS119W are warranted, as this approach would allow administration of greater total doses of KS119W over the course of fractionated radiotherapy. Studies of the toxicities of KS119W given in these more extensive fractionated regimens would also be needed. Studies of the pharmacokinetics, distribution, and toxicology of this new agent would be needed to assess the potential utility of KS119W in the therapy of solid malignancies and to plan optimal regimens for combining KS119W with radiation. Our data also suggest the need for studies using other experimental model tumor systems, including both syngeneic rodent tumors and human tumor xenografts, to assess the generality of the observed effects.
In summary, the large differential in the toxicities of KS119W to aerobic and severely hypoxic EMT6 cells, and the promising findings from these preliminary studies with tumors in mice indicate that additional studies are warranted to define the effects of this novel bioreductive alkylating agent more completely, and to better assess the potential therapeutic value of KS119W as an adjunct to radiation therapy in the treatment of solid tumors.
